Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewUBP 301
Description: Kainate antagonist
Chemical Name: (αS)-α-Amino-3-[(4-carboxyphenyl)methyl]-3,4-dihydro-5-iodo-2,4-dioxo-1(2H)-pyrimidinepropanoic acid
Purity: ≥98% (HPLC)
Biological Activity for UBP 301
UBP 301 is a potent kainate receptor antagonist (apparent Kd = 5.94 μM). Displays ~ 30-fold selectivity over AMPA receptors.
Technical Data for UBP 301
| M. Wt | 459.2 |
| Formula | C15H14IN3O6 |
| Storage | Store at +4°C |
| Purity | ≥98% (HPLC) |
| CAS Number | 569371-10-4 |
| PubChem ID | 6604913 |
| InChI Key | JHSYCOCOIYSZGI-NSHDSACASA-N |
| Smiles | O=C(C(I)=CN1C[C@H](N)C(O)=O)N(CC2=CC=C(C(O)=O)C=C2)C1=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for UBP 301
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 2.3 | 5 with gentle warming |
Preparing Stock Solutions for UBP 301
The following data is based on the product molecular weight 459.2. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 0.05 mM | 43.55 mL | 217.77 mL | 435.54 mL |
| 0.25 mM | 8.71 mL | 43.55 mL | 87.11 mL |
| 0.5 mM | 4.36 mL | 21.78 mL | 43.55 mL |
| 2.5 mM | 0.87 mL | 4.36 mL | 8.71 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for UBP 301
References for UBP 301
References are publications that support the biological activity of the product.
More et al (2003) Structural requirements for novel willardiine derivatives acting as AMPA and kainate receptor antagonists. Br.J.Pharmacol. 138 1093 PMID: 12684265
If you know of a relevant reference for UBP 301, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: UBP 301, UBP 301 supplier, Kainate, receptor, antagonists, Glutamate, Receptors, iGluR, Ionotropic, UBP301, 1766, Tocris Bioscience
1 Citation for UBP 301
Citations are publications that use Tocris products. Selected citations for UBP 301 include:
Cassé et al (2012) Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals. J Neurosci 32 5186 PMID: 22496564
Do you know of a great paper that uses UBP 301 from Tocris? Please let us know.
Reviews for UBP 301
There are currently no reviews for this product. Be the first to review UBP 301 and earn rewards!
Have you used UBP 301?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Ion Channel Product Listing
A collection of around 500 products for ion channel research, the listing includes research tools for the study of:
- Ligand-gated ion channels
- Voltage-gated ion channels
- Other Ion Channels
Pain Research Product Guide
A collection of over 280 products for pain research, the guide includes research tools for the study of:
- Nociception
- Ion Channels
- G-Protein-Coupled Receptors
- Intracellular Signaling
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Epilepsy Poster
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Pain Poster
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia Poster
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.